Endogenous/exogenous dual-responsive nanozyme for photothermally enhanced ferroptosis-immune reciprocal synergistic tumor therapy
Science Advances · 16.05.2025 · 11 (20)
DOI: 10.1126/sciadv.adq3870 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 16.05.2025. Verfasst von Hanxi Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology & Cancer Institute, Sichuan Provincial People's Hospital, and School of Life Science and Technology, University of Electronic …. Hauptthemen laut MEDLINE: Ferroptosis, Neoplasms, Photothermal Therapy, Nanoparticles. Die Arbeit wurde bisher 81-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Apoptosis resistance and immune evasion of tumor cells substantially increase the risk of cancer treatment failure. Here, a multifunctional nanozyme MET-CMS@FeTA (MCMSFT) formulated to induce nonapoptotic ferroptosis and boost immune recognition/attack, where compensatory mechanisms collectively overcome intrinsic tumor therapeutic limitations and improve medical intervention outcomes. Leveraging the multienzyme-like activity of MCMSFT to achieve oxygen generation, hydroxyl radical production, and glutathione depletion promotes hypoxia relief and triggers apoptosis/ferroptosis. Notably, MCMSFT-mediated photothermal therapy (PTT) facilitates direct tumor thermal ablation and offers exogenous heat to accelerate nanocatalytic reactions. Furthermore, PTT/ferroptosis-caused immunogenic cell death favors antitumor immunity initiation. Simultaneously, metformin administration and hypoxia amelioration down-regulate programmed death ligand 1 alleviating immune evasion. Interferon-γ secretion poses positive feedback to ferroptosis, thereby establishing a ferroptosis-immune mutual amplification loop. Antitumor performances illustrate that MCMSFT eliminates primary tumors and suppresses metastasis/rechallenge tumors. Collectively, MCMSFT surmounts the predicament of apoptosis resistance and immune evasion in cancer treatment to acquire more effective and comprehensive therapy efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Oncology & Cancer Institute, Sichuan Provincial People's Hospital, and School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 610054, Sichuan, P. R. China.
- TCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, No. 39 Shi-er-qiao Road, Chengdu 610072, Sichuan, P. R. China.
- Department of Urology, Deyang People's Hospital, Deyang 618099, Sichuan, P. R. China.
ORCID-Profile: Hanxi Zhang, Hao Wu, Mengyue Li, Chunhui Wu, Dong Lv, Yiyao Liu, Hong Yang
Zitieren
APA
Zhang, H., Lv, J., Wu, H., He, Y., Li, M., Wu, C., Lv, D., Liu, Y., & Yang, H. (2025). Endogenous/exogenous dual-responsive nanozyme for photothermally enhanced ferroptosis-immune reciprocal synergistic tumor therapy. Science Advances, 11(20). https://doi.org/10.1126/sciadv.adq3870
Vancouver
Zhang H, Lv J, Wu H, He Y, Li M, Wu C, et al. Endogenous/exogenous dual-responsive nanozyme for photothermally enhanced ferroptosis-immune reciprocal synergistic tumor therapy. Science Advances. 2025;11(20). doi:10.1126/sciadv.adq3870
BibTeX
@article{Zhang2025,
author = {Zhang, Hanxi and Lv, Jiazhen and Wu, Hao and He, Yuhan and Li, Mengyue and Wu, Chunhui and Lv, Dong and Liu, Yiyao and Yang, Hong},
title = {Endogenous/exogenous dual-responsive nanozyme for photothermally enhanced ferroptosis-immune reciprocal synergistic tumor therapy},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {20},
doi = {10.1126/sciadv.adq3870}
}
EUVIMED